Xintela AB (1XT)
Market Open
12 Aug, 06:04
XFRA XFRA Primary €
0. 00
+0
+9.0909%
€
8.02M Market Cap
- P/E Ratio
- Div Yield
32,574 Volume
- Eps
€ 0
Previous Close Want to track 1XT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
1XT trading today higher at €0, an increase of 9.0909% from yesterday's close, completing a monthly decrease of -33.3333% or €0. Over the past 12 months, 1XT stock lost -66.1972%.
1XT is not paying dividends to its shareholders.
The last earnings report, released on May 08, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Xintela AB (1XT) FAQ
What is the stock price today?
The current price is €0.00.
On which exchange is it traded?
Xintela AB is listed on XFRA.
What is its stock symbol?
The ticker symbol is 1XT.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 8.02M.
Has Xintela AB ever had a stock split?
No, there has never been a stock split.
Xintela AB Profile
| Biotechnology Industry | Healthcare Sector | - CEO | XFRA Exchange | SE0007756903 ISIN |
| Sweden Country | 21 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Xintela AB (publ) is a pioneering biopharma company established in 2009 and located in Lund, Sweden. The company specializes in the development of innovative medical products focusing on two significant areas: stem cell therapy and targeted cancer therapy. With its dedication to addressing complex health challenges, Xintela is at the forefront of creating therapeutic solutions aimed at improving patient outcomes in various diseases.
Products and Services
The company’s portfolio includes several advanced products in different stages of development, notably in stem cell therapy and cancer treatment:
- XSTEM: A flagship product in Phase I/IIa clinical development aimed at treating knee osteoarthritis. This stem cell therapy shows promise in regenerating damaged knee tissue, potentially offering relief to millions suffering from the debilitating condition. Additionally, XSTEM is under clinical investigation for the treatment of hard-to-heal leg ulcers and acute respiratory distress syndrome, exploring its efficacy in various medical indications.
- EQSTEM: Specifically designed for equine health, EQSTEM is in the preclinical development stage for treating joint diseases in horses. This product leverages stem cell technology to address a significant need in veterinary medicine, promising improved outcomes for equine joint health.
- TARG9 and TARG10: These are antibody-based cancer therapies in the preclinical study phase targeting aggressive and hard-to-treat cancers. TARG9 is focused on triple-negative breast cancer, a form of cancer that lacks three common receptors known to fuel most breast cancer growth, making it particularly challenging to treat. TARG10 is being developed to combat glioblastoma, a highly malignant brain tumor characterized by its rapid growth and resistance to existing therapies. Both products embody Xintela's commitment to advancing cancer treatment through targeted approaches.
Contact Information
Address: Medicon Village
Phone: 46 4 62 75 65 00
Website: https://www.xintela.se
